Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanologica AB ( (SE:NICA) ) just unveiled an update.
Nanologica’s nomination committee has proposed Mark Quick, a partner at Flerie AB with extensive M&A and corporate development experience from Recipharm and other pharma companies, and Erik Haeffler, CEO of APL and former manufacturing and sustainability executive at Recipharm, AstraZeneca and Meda, as new board members. The committee also proposes existing director Thomas Eldered as new chairman and recommends the re-election of Gisela Sitbon, Thomas Eldered, Mattias Bengtsson, Lena Torlegård and Jeremie Trochu, while current board member Anders Rabbe declines re-election, signaling a refreshed board composition ahead of the 21 May 2026 AGM that strengthens Nanologica’s industrial, manufacturing and deal-making expertise in its expanding peptide purification niche.
The most recent analyst rating on (SE:NICA) stock is a Sell with a SEK0.36 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced chromatographic consumables to pharmaceutical manufacturers. Its products are tailored for purification of peptide drugs such as insulin and GLP-1 analogues, targeting a growing global niche market driven by rising demand for diabetes and obesity treatments.
Average Trading Volume: 191,481
Technical Sentiment Signal: Sell
Current Market Cap: SEK113.1M
See more insights into NICA stock on TipRanks’ Stock Analysis page.